Vera Therapeutics Stock Performance
| VERA Stock | USD 41.76 0.39 0.93% |
On a scale of 0 to 100, Vera Therapeutics holds a performance score of 12. The entity has a beta of 1.66, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vera Therapeutics will likely underperform. Please check Vera Therapeutics' skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether Vera Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vera Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, Vera Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.93) | Five Day Return (2.29) | Year To Date Return (14.11) | Ten Year Return 263.13 | All Time Return 263.13 |
1 | Disposition of 100 shares by Fordyce Marshall of Vera Therapeutics at 51.2 subject to Rule 16b-3 | 11/21/2025 |
2 | Insider Trading | 11/25/2025 |
3 | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 12/05/2025 |
4 | Wells Fargo sees short squeeze ahead here are three stocks to play it - CryptoRank | 01/06/2026 |
5 | Vera Therapeutics, Inc. Granted FDA Priority Review For Atacicept | 01/15/2026 |
6 | Y Intercept Hong Kong Ltd Takes 1.95 Million Position in Vera Therapeutics, Inc. VERA | 01/29/2026 |
7 | Is Vera Therapeutics One of the Best High Short Interest Stocks with Biggest Upside Potential | 01/30/2026 |
8 | Acquisition by Brenner Robert of 50000 shares of Vera Therapeutics at 42.74 subject to Rule 16b-3 | 02/04/2026 |
9 | Analysts Bullish on Vera Therapeutics Amid New Commercial Chief Appointment | 02/19/2026 |
| Begin Period Cash Flow | 45.7 M | |
| Total Cashflows From Investing Activities | -425 M |
Vera Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,924 in Vera Therapeutics on November 23, 2025 and sell it today you would earn a total of 1,252 from holding Vera Therapeutics or generate 42.82% return on investment over 90 days. Vera Therapeutics is currently generating 0.6801% in daily expected returns and assumes 4.2163% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Vera, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vera Therapeutics Target Price Odds to finish over Current Price
The tendency of Vera Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 41.76 | 90 days | 41.76 | about 60.76 |
Based on a normal probability distribution, the odds of Vera Therapeutics to move above the current price in 90 days from now is about 60.76 (This Vera Therapeutics probability density function shows the probability of Vera Stock to fall within a particular range of prices over 90 days) .
Vera Therapeutics Price Density |
| Price |
Predictive Modules for Vera Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vera Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Vera Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Vera Therapeutics is not an exception. The market had few large corrections towards the Vera Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vera Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vera Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.54 | |
β | Beta against Dow Jones | 1.66 | |
σ | Overall volatility | 7.07 | |
Ir | Information ratio | 0.14 |
Vera Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vera Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vera Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Vera Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (152.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Vera Therapeutics currently holds about 131.93 M in cash with (134.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86. | |
| Vera Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Analysts Bullish on Vera Therapeutics Amid New Commercial Chief Appointment |
Vera Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vera Stock often depends not only on the future outlook of the current and potential Vera Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vera Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 55.3 M | |
| Cash And Short Term Investments | 640.9 M |
Vera Therapeutics Fundamentals Growth
Vera Stock prices reflect investors' perceptions of the future prospects and financial health of Vera Therapeutics, and Vera Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vera Stock performance.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 2.58 B | ||||
| Shares Outstanding | 70.99 M | ||||
| Price To Earning | 17.01 X | ||||
| Price To Book | 7.50 X | ||||
| EBITDA | (144.42 M) | ||||
| Net Income | (152.15 M) | ||||
| Cash And Equivalents | 131.93 M | ||||
| Cash Per Share | 4.86 X | ||||
| Total Debt | 54.64 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 8.24 X | ||||
| Book Value Per Share | 6.24 X | ||||
| Cash Flow From Operations | (134.68 M) | ||||
| Earnings Per Share | (3.99) X | ||||
| Market Capitalization | 2.99 B | ||||
| Total Asset | 655.68 M | ||||
| Retained Earnings | (461.25 M) | ||||
| Working Capital | 625.85 M | ||||
| Current Asset | 237.64 M | ||||
| Current Liabilities | 54.04 M | ||||
About Vera Therapeutics Performance
By analyzing Vera Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Vera Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Vera Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vera Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.30) | (0.32) |
Things to note about Vera Therapeutics performance evaluation
Checking the ongoing alerts about Vera Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vera Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vera Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (152.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Vera Therapeutics currently holds about 131.93 M in cash with (134.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86. | |
| Vera Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Analysts Bullish on Vera Therapeutics Amid New Commercial Chief Appointment |
- Analyzing Vera Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vera Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Vera Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vera Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vera Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vera Therapeutics' stock. These opinions can provide insight into Vera Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Vera Stock analysis
When running Vera Therapeutics' price analysis, check to measure Vera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vera Therapeutics is operating at the current time. Most of Vera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vera Therapeutics' price. Additionally, you may evaluate how the addition of Vera Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |